Market Overview

CRISPR/Cas in Therapeutics & Cellular Studies, 2018 Research Report - ResearchAndMarkets.com

Share:

The "CRISPR/Cas
in Therapeutics & Cellular studies"
report has been added
to ResearchAndMarkets.com's offering.

Over the last few decades, Gene editing took a new turn with the
discovery of CRISPR and its variant Cas9. CRISPR not only gave a new
image to gene editing but also raised the standards for new findings.
CRISPR has been widely used for study or treatment of various diseases
viz. Cancer, Huntington's disease, infectious diseases etc. CRISPR
together with stem cell are widely been employed for creation of disease
models, multiple tissue engineering tasks.

The influencing factor for the escalated growth of CRISPR-Cas system are
progressive gene therapy, disease prevalence, grants/funding etc. The
present report studies application of CRISPR in therapeutics & Cellular
studies in past 20 years.

The key players (Maximum filing) in CRISPR-Cas system based
therapeutics/ cellular studies are: Broad institute, MIT, Harvard
college, University California, Regeneron pharma etc.

Key Topics Covered:

1. Executive Summary

2. Technology Overview

3. CRISPR/Cas in Therapeutics & Cellular studies

4. Trends & Future Perspectives

Companies Mentioned

  • Broad institute
  • MIT
  • Harvard college
  • University California
  • Regeneron pharma

For more information about this report visit https://www.researchandmarkets.com/research/kmlmtv/crisprcas_in?w=4

View Comments and Join the Discussion!